I have not gone into details of the differences but as far as I know they have the same mechanism of action. Positive for ALBO is: 1. That it is given 1 times daily in comparison to 2 times daily for Mirum. 2. In addition, looking at the A4250 results earlier it seems like ALBO has found a therapeutic window, considering the low level of adverse events. It is hard to do so, for this mechanism, and might be a problem for NASH (next study) but it really seems like ALBO has the competent people to find the window. I do not yet know about Mirum, but it IS hard... let us see what the future brings. 3. The most potent IBAT inhibitor, giving it potential benefits for hitting other indications/Adults. There are limitations with non-potent inhibitors. 4. They are probably a year in advance compared to Mirium (Ph3).
|